JP2022506829A5 - - Google Patents
Info
- Publication number
- JP2022506829A5 JP2022506829A5 JP2021524438A JP2021524438A JP2022506829A5 JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5 JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758388P | 2018-11-09 | 2018-11-09 | |
| US62/758,388 | 2018-11-09 | ||
| PCT/US2019/061010 WO2020097625A1 (en) | 2018-11-09 | 2019-11-12 | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506829A JP2022506829A (ja) | 2022-01-17 |
| JP2022506829A5 true JP2022506829A5 (https=) | 2022-11-21 |
| JPWO2020097625A5 JPWO2020097625A5 (https=) | 2022-11-21 |
Family
ID=70612537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524438A Pending JP2022506829A (ja) | 2018-11-09 | 2019-11-12 | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210267986A1 (https=) |
| EP (1) | EP3877422A4 (https=) |
| JP (1) | JP2022506829A (https=) |
| CN (1) | CN113271977A (https=) |
| WO (1) | WO2020097625A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| CN114748480B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102051881B1 (ko) * | 2010-10-25 | 2019-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| MX2015007185A (es) * | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| AU2015225436A1 (en) * | 2014-03-03 | 2016-09-08 | Eisai R&D Management Co., Ltd. | Use of eribulin and mTOR inhibitors as combination therapy for the treatment of cancer |
| WO2015161285A1 (en) * | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| RU2699545C2 (ru) * | 2014-05-28 | 2019-09-06 | ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД | Применение эрибулина в лечении рака |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US20160166536A1 (en) * | 2014-12-12 | 2016-06-16 | Northwestern University | Combination therapy for the treatment of cancer |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| EP3487492A4 (en) * | 2016-07-20 | 2020-03-11 | Eisai R&D Management Co., Ltd. | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| IL303038B2 (en) * | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) * | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| US20180371021A1 (en) * | 2017-05-11 | 2018-12-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
-
2019
- 2019-11-12 JP JP2021524438A patent/JP2022506829A/ja active Pending
- 2019-11-12 EP EP19881900.5A patent/EP3877422A4/en not_active Withdrawn
- 2019-11-12 WO PCT/US2019/061010 patent/WO2020097625A1/en not_active Ceased
- 2019-11-12 CN CN201980088426.8A patent/CN113271977A/zh active Pending
-
2021
- 2021-05-07 US US17/315,011 patent/US20210267986A1/en not_active Abandoned